Samsung Biologics삼성바이오로직스
207940 · KOSPI · ₩SBL · 삼성바이오로직스
Analyst target price
Average target
₩1,962,500
Upside
+42.8%
Range ₩1,900,000 – ₩2,000,000 · 4 brokers (latest target within 6 months)
Buy 2
Consensus target vs price, 2 years
Earnings estimates
Brokers' earnings estimates and how they've been revised, with Pro.
Unlock with ProBroker reports
| Date | Broker | Report | Rating | Target | Change | Upside | Since publish | Read |
|---|---|---|---|---|---|---|---|---|
| Oct 22 | Yuanta Securities Korea | Maintaining Growth Potential in an Unfavorable Environment | Buy | ₩2,000,000 | Maintained | +45.6% | +1.0% | Read ↗ |
| Oct 12 | Heungkuk Securities | [Pharma/Bio/Cosmetics] Samsung Biologics: Steady CMO mid- to long-term earnings outlook | — | — | — | +14.4% | Read ↗ | |
| Oct 8 | Kyobo Securities | 3Q26 Preview: Order resumption expected; in line with consensus despite falling exchange rate | Buy | ₩1,900,000 | Maintained | +38.3% | +12.7% | Read ↗ |
All 7 broker reports on Samsung Biologics, not just the latest 3, with Pro.
Unlock with ProCalculated by JONBUR from publicly available broker reports. Reports belong to their publishers. Not financial advice. Includes brokers that publish research publicly; some brokers' reports are client-only and not included.
Reported in the news
| Date | Broker | Target | Change | Rating | Source |
|---|---|---|---|---|---|
| Oct 21 | — | ₩2,000,000 | — | Reported by Seoul Economic Daily | |
| Oct 21 | — | ₩1,900,000 | — | Reported by The Financial News | |
| Oct 21 | Daishin Securities | ₩2,000,000 | — | Reported by The Korea Economic Daily | |
| Oct 13 | Korea Investment & Securities | ₩1,950,000 | Raised | — | Reported by Chosun Biz |
Target prices and ratings as news headlines report them, for every broker, including the ones whose reports we don't collect. Only what the headline says; open the article for the rest. Not financial advice.
AI summary of public information
An AI summary of the public information on this company: filed financial statements, filings, prices and news headlines. It doesn't use broker reports; their targets and estimates are shown above.
Samsung Biologics reports strong trailing profitability, but its share price remains well below its 52-week high amid labour and valuation concerns.
Samsung Biologics is a Korean contract drug manufacturer whose trailing twelve-month figures to H1 2026 show revenue of about ₩4.5T, an operating margin of 50% and net income of about ₩2.0T. The shares closed at ₩1,466,000 on 23 October 2026, up 7.3% over one month but down 14.3% over one year, and trade at a trailing P/E of 34.2 and P/B of 8.1.
What stands out
- Trailing revenue of ₩4.5T is roughly flat against the 2025 full-year figure of ₩4.6T, so recent growth is modest on this measure.
- Operating margin rose from 29% in 2024 to 45.4% in 2025 and reached 50% on a trailing basis to H1 2026.
- The filed DCF base value is ₩577,784, well below the closing price, while the bull case is ₩854,794; the data does not explain the gap beyond the model assumptions.
- Foreign ownership eased slightly to 12.7% from 13% sixty days earlier, and 20-day flows show net foreign selling of about ₩294B against net institutional buying of about ₩331B.
- Analyst target prices of ₩1.9M to ₩2M appeared in news headlines; these are reported third-party views, not forecasts from this summary.
What to watch
- Labour dispute: a union statement on court security measures and the right to strike was reported on 26 October, and the data does not give the outcome.
- Customer orders and 2027 outlook, which news reports say the market is watching; no company guidance details are in the data beyond a reported 20% revenue growth target.
- Balance sheet: borrowings of ₩965B against cash of ₩289B, and bond investor attention noted in one headline.
Data as of Oct 23, 2026 · written 2d ago
This is not financial advice.
Also known as: Samsung Biologics / 삼성바이오로직스 / 207940 / KRX:207940
Source: KRX statistical information